We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,324

Dentons' pick of global regulatory trends to watch in 2017
  • Dentons
  • Australia, Canada, China, European Union, Germany, Mexico, OECD, United Kingdom, USA
  • February 9 2017

Dentons’ team of regulatory lawyers from key jurisdictions around the world weigh in on regulatory trends to watch in 2017 in the US, Europe, the UK


CIALIS Patent Survives Validity Challenge on Appeal
  • McCarthy Tétrault LLP
  • Canada
  • May 19 2016

Last year we wrote about a trilogy of Federal Court decisions relating to Eli Lilly’s erectile dysfunction (ED) drug CIALIS (tadalafil). While Lilly


Competitionantitrust law
  • Dentons
  • European Union, Germany, OECD, United Kingdom, USA, Australia, Canada, China
  • February 9 2017

In the wake of the 2016 elections, we now await the decision as to who will be the "antitrust guard" at the top of the US Department


Federal Court of Appeal rules on non-infringing alternatives and apportionment as defences to an accounting of profits from patent infringement
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • February 21 2017

On February 2, 2017, the Federal Court of Appeal released a significant decision on Accounting for profits, a remedy for patent infringement in


Federal Court dismisses AstraZeneca’s prohibition application against Mylan’s naproxen-esomeprazole magnesium tablet product
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • January 30 2017

In reasons released February 7, 2017, the Federal Court dismissed AstraZeneca's application for a prohibition order regarding Mylan's


Cialis Canadian Patent Knocks Out Double Patenting Challenge
  • Bereskin & Parr LLP
  • Canada
  • January 20 2017

Eli Lilly's Canadian patent on treatment of erectile dysfunction with Cialis continues to defy all challengers. A recent appeal case originated from


Federal Court dismisses Apotex’s application for judicial review regarding Apo-Progesterone ANDS
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • January 30 2017

On February 1, 2017, the Federal Court dismissed Apotex's application for judicial review of the Minister of Health's refusal to approve its


PMPRB News
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • January 30 2017

Decision striking Alexion pleading challenging constitutionality of PMPRB regime upheld. On December 28, 2016, the Federal Court dismissed Alexion's


Decision of Minister of Health Rejecting ANDS Upheld
  • Borden Ladner Gervais LLP
  • Canada
  • February 22 2017

Apotex sought judicial review of a decision of the Minister of Health that had the effect of rejecting its Abbreviated New Drug Submission (ANDS) for


International Trade Compliance Update - September 2016
  • Baker McKenzie
  • European Union, United Kingdom, USA, Australia, Canada
  • September 7 2016

On 19 August 2016, the Russian Federation notified the WTO that it intends to initiate negotiations pursuant to Paragraph 1143 of the Working Party